ClinicalTrials.gg
Not yet recruitingNCT07733791RECOVERUpdated Jul 30, 2026

Real-world Evidence of Cannabinoid for Observed Pain Relief

An observational study in Chronic Musculoskeletal Pain and Delayed Onset Muscle Soreness (DOMS), sponsored by Associação Pan-Americana Multidisciplinar de Endocanabinologia. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-30.

Primary conditionMyalgiaRegistry: Musculoskeletal PainReclassifiedWhy we changed it
Registry
Musculoskeletal Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Myalgia
Why
  1. The study's listed conditions name Myalgia, a narrower term within Musculoskeletal Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Associação Pan-Americana Multidisciplinar de Endocanabinologia · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
60
Ages
18 Years and older
Sex
All
01

Study summary

Chronic muscle pain is one of the most prevalent clinical challenges in sports medicine, significantly affecting training capacity, competitive performance, and quality of life in athletes.

The endocannabinoid system has emerged as a promising therapeutic target for pain modulation in the sports context.

This prospective, comparative, non-randomized observational study aims to evaluate whether adjuvant topical application of a cannabinoid balm (CBD:THC 3:1 - Papa \& Barkley) provides additional reduction in chronic muscle pain intensity in athletes, compared to systemic CBD oil alone, over 90 days of follow-up in a real-world clinical practice setting.

Sixty adult athletes (amateur or professional) with established chronic muscle pain (≥3 months) who receive clinical indication for cannabinoid therapy will be followed in two observational cohorts: Cohort A (n=30), receiving only systemic CBD oil (60 mg/day oral/sublingual), and Cohort B, (n=30) receiving systemic CBD oil plus the topical cannabinoid balm (CBD:THC 3:1, applied twice daily to the affected muscle area).

Treatment allocation is based exclusively on the clinical decision of the principal investigator, reflecting routine medical practice. The primary outcome is the change in Brief Pain Inventory (BPI) scores from baseline (D0) to end of follow-up (D90). Secondary outcomes include pain intensity (NRS), sleep quality (PSQI), quality of life (SF-36), perceived muscle recovery (TQR scale), functional capacity (LEFS/UEFI), rescue analgesic use, and safety/tolerability of the topical formulation.

The study aims to generate real-world evidence on the effectiveness and safety of adjuvant topical cannabinoid therapy in athletes with chronic muscle pain in the Brazilian clinical practice setting.

Read the detailed description

BACKGROUND:

Chronic muscle pain affects up to 70% of amateur and professional athletes over 12 months, with 7-day prevalence rates of approximately 32.8%. Conventional pharmacological therapies (NSAIDs, muscle relaxants, opioids) frequently provide inadequate relief and are associated with limiting systemic adverse effects. The endocannabinoid system (ECS) has emerged as a promising therapeutic target, with CB1 and CB2 receptors playing key roles in nociceptive modulation and neuroinflammation attenuation.

Topical cannabinoid administration offers the advantage of delivering high concentrations directly to peripheral receptors (CB1, CB2, and TRPV1) in nerve endings and immune cells of the skin and underlying muscle tissue, while minimizing systemic absorption. The combination of CBD and THC in a 3:1 ratio may maximize synergistic therapeutic effects (entourage effect) while mitigating psychotropic adverse effects.

STUDY DESIGN:

This is a prospective, comparative, non-randomized observational study with 90 days of follow-up per participant. Treatment allocation is based exclusively on the principal investigator's clinical decision, reflecting routine medical practice.

POPULATION:

60 adult athletes (amateur or professional) practicing structured physical activity (≥3 sessions/week) for at least 6 months, with clinically confirmed chronic muscle pain (≥3 months duration), including myofascial pain syndrome, recurrent persistent DOMS, or pain from overtraining/repetitive microtrauma.

INTERVENTIONS OBSERVED:

Cohort A (Control, n=30): Full spectrum CBD oil, 60 mg/day, oral/sublingual, once daily at bedtime, for 90 days.

Cohort B (Intervention, n=30): Full spectrum CBD oil (same as Cohort A) PLUS Papa \& Barkley Topical Balm (450 mg CBD + 150 mg THC per 50 mL bottle; 9 mg CBD + 3 mg THC per mL), applied twice daily (every 12 hours) to the affected muscle area for 90 days.

ASSESSMENTS:

Evaluations at D0 (baseline), D7, D14, D30, D60, and D90 using validated instruments including BPI, NRS (0-10), PSQI, SF-36, TQR scale, LEFS/UEFI, rescue analgesic quantification, and structured adverse event reporting.

STATISTICAL ANALYSIS:

Mixed-effects models for repeated measures (MMRM) or Generalized Estimating Equations (GEE) will be used. Propensity score matching may be employed to mitigate confounding bias. Pre-specified subgroup analyses by sport modality, pain location, competitive level, and training volume.

ETHICS:

The protocol will be submitted to the Research Ethics Committee (CEP) via Plataforma Brasil, following CNS Resolutions 466⁄2012 and 510⁄2016.

Results will be reportedfollowing STROBE guidelines for observational studies.

02

Conditions studied

  • Chronic Musculoskeletal Pain
  • Delayed Onset Muscle Soreness (DOMS)

Browse trials for

Keywords

  • Topical Cannabinoids
  • Systemic Cannabidiol
03

In context

Myalgia Reclassified

256 studies on the registry are indexed under Myalgia; 45 are open to participants now.

This study's planned enrollment of 60 is below the median of 196 across 35 observational studies indexed under Myalgia.

Browse Myalgia studies →

Lead sponsor

Associação Pan-Americana Multidisciplinar de Endocanabinologia is the lead sponsor of 4 studies on the registry; 4 are open to participants now.

Compared within Myalgia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Musculoskeletal Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult athletes (amateur or professional) practicing structured physical activity (minimum 3 sessions per week) for at least 6 months, with performance, competition, or high physical performance objectives, and with an established clinical diagnosis of chronic muscle pain (≥3 months duration). Participants are recruited from the clinical practice of the principal investigator in Brazil.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Predominantly articular, bone, or non-muscular pain (e.g., fractures, degenerative arthropathies)
  • Presence of open skin lesions, infections, or active dermatoses at the topical application site
  • Current use of WADA-prohibited substances that may interfere with outcome assessment
  • Athletes in official competition during the study period using THC-containing formulations (due to WADA in-competition prohibition)
  • Severe acute musculoskeletal injury (complete muscle rupture, fracture) within the last 30 days
  • Cognitive or technological inability to use the follow-up platform

Exclusion criteria

Exclusion Criteria:

  • Predominantly articular, bone, or non-muscular pain (e.g., fractures, degenerative arthropathies)
  • Presence of open skin lesions, infections, or active dermatoses at the topical application site
  • Current use of WADA-prohibited substances that may interfere with outcome assessment
  • Athletes in official competition during the study period using THC-containing formulations (due to WADA in-competition prohibition)
  • Severe acute musculoskeletal injury (complete muscle rupture, fracture) within the last 30 days
  • Cognitive or technological inability to use the follow-up platform
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
60 participants (estimated)
Target follow-up
90 Days
Patient registry
Yes

Groups and cohorts

  • Systemic CBD only - Control

    Athletes receiving standard cannabinoid therapy only: Full spectrum CBD oil 60 mg/day (1 mL), oral/sublingual, once daily at bedtime, for 90 continuous days. No topical cannabinoid formulation prescribed.

  • Systemic CBD + Topical Balm (Intervention)

    Athletes receiving standard cannabinoid therapy (Full spectrum CBD oil 60 mg/day oral/sublingual) plus adjuvant topical Papa \& Barkley Cannabinoid Balm (CBD:THC 3:1; 9 mg CBD + 3 mg THC per mL), applied twice daily (every 12 hours) to the affected muscle area, for 90 continuous days.

06

What researchers measure

Primary outcomes

  1. Change in Chronic Muscle Pain Intensity and Interference (Brief Pain Inventory)

    Change in Brief Pain Inventory (BPI) scores - pain intensity dimension (worst, least, average, current pain on 0-10 scale) and pain interference dimension (7 items on 0-10 scale assessing interference with general activity, mood, walking, work, relations, sleep, and enjoyment of life) - from baseline (D0) to end of follow-up (D90). Higher scores indicate worse pain/interference. A clinically meaningful change is defined as ≥2 points reduction in pain intensity.

    Time frame: From baseline (Day 0) to end of follow-up (Day 90)

Secondary outcomes

  1. Pain Intensity (Numeric Rating Scale)

    Pain intensity measured by the Numeric Rating Scale (NRS 0-10), where 0 = no pain and 10 = worst imaginable pain. Assessed at D0, D7, D14, D30, D60, and D90.

    Time frame: From baseline (Day 0) to Day 90, with assessments at Days 7, 14, 30, 60, and 90

  2. Sleep Quality (Pittsburgh Sleep Quality Index - PSQI)

    Sleep quality measured by the Pittsburgh Sleep Quality Index (PSQI). The PSQI is a self-report questionnaire assessing sleep quality over a 1-month interval, consisting of 19 items creating 7 components producing a global score (0-21). Scoring: 0-5 = good sleep quality; 6- 10 = poor sleep quality; 11-21 = sleep disorder indication. Lower scores indicate better sleep quality.

    Time frame: From baseline (Day 0) to Day 90, with assessments at Days 30, 60, and 90

  3. Quality of Life (SF-36)

    Health-related quality of life measured by the Medical Outcomes Study 36-Item Short-Form Health Survey (SF-36). The SF-36 assesses 8 physical and mental health domains, scored from 0 (worst health) to 100 (best health). Higher scores indicate better quality of life.

    Time frame: From baseline (Day 0) to Day 90, with assessments at Days 30, 60, and 90

  4. Perceived Muscle Recovery (Total Quality Recovery - TQR Scale)

    Perceived muscle recovery measured by the Total Quality Recovery (TQR) scale of Kenttä \& Hassmén. The TQR is a single-item scale (6-20) that assesses the athlete's perceived recovery status. Higher scores indicate better perceived recovery (6 = very, very poor recovery; 20 = very, very good recovery).

    Time frame: From baseline (Day 0) to Day 90, with assessments at Days 7, 14, 30, 60, and 90

  5. Sports Functional Capacity (LEFS/UEFI)

    Sports functional capacity measured by the Lower Extremity Functional Scale (LEFS) or Upper Extremity Functional Index (UEFI), according to pain location. LEFS: 0-80 scale (higher = better function). UEFI: 0-80 scale (higher = better function).

    Time frame: From baseline (Day 0) to Day 90, with assessments at Days 30, 60, and 90

  6. Safety and Tolerability (Adverse Events)

    Structured recording of local and systemic adverse events, classified by severity (mild, moderate, severe) and causal relationship (definite, probable, possible, unlikely, unrelated). Includes monitoring of local skin reactions (dryness, erythema, pruritus, rash) and systemic effects (somnolence, diarrhea, nausea, appetite changes).

    Time frame: From Day 7 to Day 90, with continuous monitoring and assessments at Days 7, 14, 30, 60, and 90

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Seevathee K, Kessomboon P, Manimmanakorn N, Luangphimai S, Thaneerat T, Wanaratna K, Plengphanich S, Thaenkham T, Sena W. Efficacy and Safety of Transdermal Medical Cannabis (THC:CBD:CBN formula) to Treat Painful Diabetic Peripheral Neuropathy of Lower Extremities. Med Cannabis Cannabinoids. 2024 Nov 14;8(1):1-14. doi: 10.1159/000542511. eCollection 2025 Jan-Dec. PubMed 39720705 ↗
  • Rojas-Valverde D, Fallas-Campos A. Cannabidiol in sports: insights on how CBD could improve performance and recovery. Front Pharmacol. 2023 Sep 22;14:1210202. doi: 10.3389/fphar.2023.1210202. eCollection 2023. No abstract available. PubMed 37808192 ↗
  • Hall N, James B, Bhuiyan MAN, Crane E, Falgout C, Murnane KS. Topical cannabidiol is well tolerated in individuals with a history of elite physical performance and chronic lower extremity pain. J Cannabis Res. 2023 Mar 30;5(1):11. doi: 10.1186/s42238-023-00179-8. PubMed 36991501 ↗

Related links

Individual participant data

Plan to share: Undecided — Individual participant data may be made available upon reasonable request to the principal investigator after study completion and publication of primary results.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for Apr 2027, 3 months later.

Of 19 observational studies under Myalgia, half reached primary completion within 14 months of starting (the median), counting those still running; a quarter within 4. This study's planned 3 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2026
First posted
Jul 29, 2026
StartEst.
Jan 1, 2027
Primary completionEst.
Apr 1, 2027
CompletionEst.
Jul 1, 2027
Last update
Jul 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07733791
Lead sponsor
Associação Pan-Americana Multidisciplinar de Endocanabinologia
Responsible party
Sponsor
First posted
Jul 29, 2026
Start date
Jan 1, 2027 (estimated)
Primary completion
Apr 1, 2027 (estimated)
Completion
Jul 1, 2027 (estimated)
Last update
Jul 30, 2026

Study contacts

Jose Wilson N V Andrade, MD
Contact
dr.jwilsonandrade@gmail.com
+55 11 971905328
Aletheia B Pablos, DDS
Contact
abpablos@gmail.com
+55 11 997426485
Jose Wilson N V Andrade, MD
principal investigator · Associação Pan-Americana Multidisciplinar de Endocanabinologia

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion